Mobidiag is actively collaborating and networking with professionals to develop rapid assays for the identification of microbes, in order to enhance current diagnostics.
Molecular methods based on amplification and hybridization of nucleic acids can solve many of the problems present in the current diagnostics for severe infections. The current diagnostics of causative agents is often time and resource consuming. Results are available only days, sometimes up to week, after sampling. In addition, current assays can be cost- and labor-intensive.
Mobidiag's first assay targeted for the detection of the causative agents of sepsis is the CE-IVD marked Prove-it™ Sepsis. In addition, Mobidiag's solution for CNSI detection is available as CE-IVD product called Prove-it™ Herpes.
The assays will at first be available as Reseach-use-only products and will be further clinically evaluated for IVD use.
Prove-it™ Biobank lays the foundation for designing different assays.
Current Prove-it™ applications are based on the PCR and microarray technologies.